ERBB2 and cancer: A total of 68 patients received taxane- and anthracycline-based chemotherapy courses, whereas 45 patients with HER2-enriched cancer received chemotherapy plus target therapies, of whom eight patients received dual blockade anti-HER2 therapy; of them, six patients achieved pathologic complete response (pCR).